AstraZeneca sales jump despite troubles in China
Sales in China fell 3 per cent during the quarter. AstraZeneca said this was mainly because the winter had been mild, causing a drop in sales of respiratory drugs used to treat viral infections. It also cited annual budget caps at Chinese hospitals.
AstraZeneca has been approached a couple of times by Chinese authorities about their investigation into the drugmaker's ...
AstraZeneca appointed a new president for its China operations following the arrest of former executive Leon Wang along with ...
The boss of drugmaker AstraZeneca has said he was “very disappointed” with the firm’s move to scrap plans for a £450 million ...
The company said, “In relation to the illegal drug importation allegations, in January 2025, AstraZeneca (AZN) received a Notice of Transfer to ...
AstraZeneca on Thursday warned that it could be fined millions of dollars in importation tax fines as Chinese authorities ...
AZ booked $540 million from Enhertu in the fourth quarter, a rise of 54%, and $1.99 billion for the full year out of total ...
Astrazeneca's revenue jumped 21 per cent last year as the pharmaceutical recorded broad growth across its key businesses.
This summary covers recent health news, including stable pig prices in Germany, investor focus on AstraZeneca's China probe, ...
AstraZeneca said the taxes related to two cancer drugs, Imfinzi and Imjudo, and that it was continuing to co-operate with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback